Amigo Mike
1 day ago
Merry Christmas and Happy Holidays Gwinner and all the long suffering ZIVO longs !!
You called $22 .... and got it 1 day later. Now calling for $200 in 2025.... welp ..... from your lips to the man upstairs ... wow that would be another 10 bagger from here. Personally I think it is doable if avian flu and a few other things fall in place. 2024 was a fantastic year if you took advantage of prices early in the year. Literally 40+ bag winner if you purchased at the lows towards the end of 2023
As mentioned, current prices are still not even at the historical company valuation of the last 5 years. And ZIVO is on the verge of gaining it's first license for coccidiosis in broiler chickens with a non antibiotic treatment.
If I'm CEO of ZIVO ....
1. I am plastering every animal pharma with information on both coccidiosis and avian flu.
2 I am also calling Kristin Peck about Zoetis' prior collaboration with ZIVO on bovine mastitis to ask .... WASSUP ?
3 Then I'm having someone in the office spam every group that can be found that is advocating for non antibiotic treatment options in the food supply and everyone writing about coccidiosis and avian flu.
4. Then I'm calling Armistice Capital and taking their temperature about exercising part of their warrants NOW .... that would bring roughly $4.2 million to ZIVO. These warrants are already in the fully diluted count for ZIVO and they expire roughly June/July 2025. But it puts $4.2 million cash in ZIVO's account and should then give them plenty of time to finish up a license for coccidiosis which would bring more money in an upfront payment and time to work on gov't grants for anything and everything including avian flu. At $50/share ... Armistice TRIPLES their money. They could "breath" on ZIVO or "whisper on Wall Street" and run it up the flagpole themselves. This would potentially eliminate the need for any dilution in 2025 and set stage for more licenses/milestone cash going forward until commercialization.
5. At $50, the public warrants are also exercisable for more cash ... and already part of the fully diluted count. These don't expire til end of May 2026
6. I'm running the next set of tests on avian flu as soon as I possibly can.
7. I am calling the new administration. RFK .... this has to be right up his alley. Federal and state gov'ts granting MILLIONS for NON solutions related to avian flu. Look it up ... it is hilarious. Welp, ZIVO might have something here. Show me the money ! And fast track via USDA. Hello HHS.
8. And I'm callin' the state of Michigan Dept of Agriculture and any state gov't dept that offers innovation grants for Michigan businesses and I'm applying for grants and I'm telling any news outlet that will listen about it. https://www.michigan.gov/mdard/animals/diseases/avian/avian-influenza
Here's one example of $200 MILLION for NON solutions in dairy cows. $200 million ... think about that.
https://www.avma.org/news/200m-federal-government-aims-stop-spread-h5n1-among-dairy-cows#:~:text=The%20U.S.%20Department%20of%20Agriculture,both%20overseen%20by%20the%20HHS.
The money thrown around in this space is CRAZY. Prior year spends from USDA 2022/2023
https://www.aphis.usda.gov/news/agency-announcements/usda-provides-additional-502-million-highly-pathogenic-avian-influenza#:~:text=The%20U.S.%20Department%20of%20Agriculture,HPAI)%20in%20the%20United%20States.
What's a potential solution worth in grants and partnership/royalties ?
Easy peasy right ? ROFLMAO !!
Amigo Mike
profiteer11
2 days ago
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Download as PDFDec 20, 2024
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
Key findings of statistical significance from the study include:
A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls.
A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.
The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI.
In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host.
These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health.
Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry.
“We are highly encouraged by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry.”
“This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.”
“With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day,” said John Payne. “We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology.”
profiteer11
2 days ago
Amigo Mike
Friday, December 20, 2024 9:33:19 AM
Post#
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Dec 20, 2024
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
Key findings of statistical significance from the study include:
A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls.
A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.
The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI.
In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host.
These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health.
Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry.
“We are highly encouraged by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry.”
“This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.”
“With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day,” said John Payne. “We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology.”
Amigo Mike
2 days ago
Well people,
I guess this is Payne's Christmas gift to shareholders breaking the silence on coccidiosis .... and the introduction of previously unknown work on avian flu which is among the hottest headlines in today animal health markets ..... and impacts humans as well. If ya don't think this is at least a $50 stock in the not too distant future ..... I dunno what to tell ya.
Payne apparently is in discussion with multiple global animal health companies for coccidiosis in broiler chickens. If ya do a little research coccidiosis is not only an issue in broiler chickens ...... so who is to say that ZIVO isn't talking about other animal species with these pharmas. I do think it is also key that these companies are going over ZIVO's patent portfolio. That due diligence can lead to a much bigger transaction .... like that buyout potential.
Then let's add avian flu to the mix. A brand new, previously unknown target for ZIVO. There are HUNDREDS OF MILLIONS in free money being thrown at avian flu. Gov't research grants. This is something that could gain traction and headlines very quickly. It could also bring sources of non dilutive money to ZIVO. My impression doing a little research over the weekend is the University of Delaware is among the top tier research facilities in the country on avian flu. My impression is also that these initial tests ..... while preliminary ...... at least with the avian flu vertical ...... are generally accepted as a very strong indicator that the product offering will be effective in it's final form. And if you read ZIVO's PR, ZIVO basically appears to have thrown multiple of its natural and bioactives at the target and found that some support different disease mgmt capabilities. So a little tweaking of the product candidate from existing ZIVO options and we might have a new non antibiotic treatment to at least mute the impacts and spread of this disease. If I am ZIVO, like I said, this info should be going out to anyone and everyone in animal pharma plus state and federal Dept of Agriculture officials, industry watch dog groups. You name it.
We are only talking animal here. And we know there are multiple human applications.
This might just be what puts ZIVO .... on the map ........ and could lead to any number of possibilities including getting bought out.
I have prior mentioned that I thought ZIVO was AT LEAST a $1 Billion (with a B) company in due time. Well the path towards that number is becoming more evident. We just need to knock down the first domino ....... and see where we go from there. That first domino should happen in the next couple months. Just to toss out some numbers .... at TODAY's outstanding number of shares (3.5 million) that is $285/ share. Fully diluted is roughly 5 million shares right now or about $200/share. And $1 Billion could be ... too low .... LOL ..... but I don't know that ZIVO would last that long without being bought out. I haven't done any research these days on natural substance buyouts but I do recall resveratrol was purchased for roughly $700 million years back. ZIVO's product candidates are all rooted in inflammation people .... and inflammation is root cause of MANY human and animal diseases. What's ZIVO's bioactives worth eh ?
Amigo Mike
Amigo Mike
2 days ago
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
Download as PDFDec 23, 2024
Expects to enter into formal negotiations with a global animal health company in January 2025 and to finalize an agreement in the first quarter of 2025
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens.
Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions with a number of major global animal health companies regarding a potential exclusive license for ZIVO’s product. Prospective licensees are actively pursuing their respective due diligence processes, including technical evaluations, patent reviews and business case assessments.
Assuming the satisfactory completion of due diligence, ZIVO expects to enter into formal negotiations next month with the goal of finalizing an agreement in the first quarter of 2025. ZIVO intends to pursue deal terms that includes an upfront payment, milestone payments tied to commercialization targets and a royalty based on product sales.
“We are focused on securing an agreement that aligns with our commercialization strategy and delivers long-term value to our shareholders. Although our license dialogues remain ongoing and there can be no assurance we will be successful in negotiating a definitive agreement, we are highly encouraged by the progress we have made over the past four months and by the level of interest expressed by prospective partners. Our product holds potential as a standalone treatment and also can enhance the efficacy of ionophores and vaccines, representing a compelling and transformative value proposition for the poultry industry,” said John B. Payne, Chairman and Chief Executive Officer of ZIVO Biosciences.
In addition, building upon last week’s announcement of preliminary efficacy against avian influenza in poultry, the Company reports that it intends to advance development work on its product candidate targeting transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry flocks. ZIVO plans to initiate additional studies at the University of Delaware to further optimize dosage and formulation, with the goal of maximizing the product’s efficacy and market readiness.
“To date our active ingredients have demonstrated effectiveness against both parasitic and viral diseases. This remarkable versatility provides distinct commercial opportunities, including as a combination product in viral indications,” added Mr. Payne.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, with the estimated annual costs in excess of $15 billion annually. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spent approximately $1.1 billion in 2024, and is estimated to grow to $1.5 billion in 2029, on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
Amigo Mike
5 days ago
Gwinner,
I couldn't agree more. Market doesn't seem to care. Friday in front of a holiday week isn't a good time for PR either.
But fantastic news nonetheless !!! Sellers pressing down on the ask.
Anyway ..... BIRD FLU ! This looks like initial testing of ZIVO's feed ingredients against bird flu in poultry. I love it when PR sez "statistically significant".
Some tidbits in there that indicate to me this was initial exploration into bird flu with multiple candidates tested to provide insight into potential options for disease management. Some reducing the viral load (already infected) some reducing spread (i.e. prevention). This is pretty big news IMO.
I like the quote from University of Delaware “This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.” Looking over the information on bird flu it appears University of Delaware might be the top US research institution on this candidate.
I also like Payne's quote at the end. “With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day,” said John Payne. “We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology.” But damn this guy is plain jane !!! More studies are warranted of course. But there are tidbits here that say .... THINGS ARE GOING ON.
Amigo Mike
Amigo Mike
5 days ago
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Download as PDFDec 20, 2024
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
Key findings of statistical significance from the study include:
A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls.
A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.
The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI.
In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host.
These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health.
Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry.
“We are highly encouraged by the outcomes of this study,” said John B. Payne, Chairman and CEO of ZIVO Bioscience. “The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry.”
“This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry,” said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. “The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue.”
“With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day,” said John Payne. “We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology.”
Amigo Mike
1 week ago
Interesting trading tape today.
All the trades posted after 10:04 AM today are listed as being posted out of sequence outside of a couple odd lots ....with all of them between 19.50 and 19.99 but not impacting the current price at the time posted ..... leaving a closing price $15.87.
Not sure what kinda games that is. Can't say I've seen that before. I've certainly seen trades posted out of sequence but this is ridiculous.
Time Price Size Type B/S Bid Price Ask Price Buy Ind. Total Volume Num Exch.
15:45:29 19.6225 100 seq Buy 17.50 19.99 2,530 22 nasd
15:43:13 19.50 100 seq Buy 17.50 19.99 2,430 21 nasd
15:17:09 19.49 100 seq Sell 19.50 19.99 2,330 20 nasd
15:12:51 19.8675 20 Buy 19.50 19.99 2,230 19 nasd
15:01:41 19.99 200 seq Buy 17.50 19.99 2,210 18 nasd
14:07:25 19.99 100 seq Buy 17.50 19.99 2,010 17 nasd
13:21:06 19.99 100 seq Buy 17.50 19.99 1,910 16 nasd
13:15:12 19.99 200 seq Buy 17.50 19.99 1,810 15 nasd
12:46:45 19.93 7 Buy 17.50 19.99 1,610 14 nasd
11:46:38 17.54 5 Sell 17.50 19.99 1,603 13 nasd
11:39:03 19.99 200 seq Buy 17.50 19.99 1,598 12 nasd
10:04:43 15.87 939 Sell 15.87 20.0000 1,398 11 nasd
10:04:38 16.71 20 Sell 18.03 20.0000 439 9 nasd
10:04:38 16.71 20 Sell 18.03 20.0000 459 10 nasd
10:04:37 18.08 100 Sell 18.03 20.0000 419 8 nasd
10:04:36 18.08 20 Sell 18.03 20.0000 319 7 nasd
10:04:31 18.08 20 Sell 18.08 20.0000 299 6 nasd
10:04:24 18.08 100 Sell 18.08 20.0000 279 5 nasd
10:04:24 18.09 99 Sell 18.08 20.0000 179 4 nasd
09:37:59 18.08 1 Sell 18.08 20.0000 80 3 nasd
09:37:28 18.10 78 Sell 18.09 20.0000 79 2 nasd
09:30:02 20.25 1 Buy 17.50 20.0000 1 1 nasd
Amigo Mike
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Ask ADVFN Intelligence (AI)
